HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 48 of 48
Dr. Lambert's research focuses on understanding the mechanisms of inherited and acquired thrombocytopenia in pediatric patients. Using clinical translational methods to link discovery in rare platelet disorders with optimizing next-generation sequencing for clinical practice, she has been involved in the Undiagnosed Disease Network Program and the Frontier Program in Immune Dysregulation, incorporating genetics of platelet disorders and immunohematology.
Dr. Laskin's research focuses on the conduct of clinical investigations and translational studies designed to target mechanisms to prevent, treat, or slow the progression of chronic kidney disease in immunosuppressed patients, including children receiving a bone marrow or kidney transplant.
Dr. Leahy studies the use of patient-reported outcomes (PROs) for symptom monitoring in pediatric oncology and how they can improve clinical outcomes. She is also interested in how PROs can be leveraged to inform predictive models for novel therapeutics, such as CAR T-cell therapy.
Dr. Leavens uses stem cell-derived beta cells to model pediatric beta cell disease, including monogenic diabetes and congenital hyperinsulinism. The goal of her studies is to better understand and develop novel therapeutics to treat these diseases.
Dr. Lefebvre investigates the genetic mechanisms that generate the diversity of cell types composing the body. Her emphasis is on deciphering how proteins called SOX transcription factors specify stem cells and highly specialized cells in the skeleton, how changes in these factors cause skeletal diseases, and how these factors also control other processes, including brain development and intellectual disability diseases.
Dr. Leff's background is in child clinical psychology, and he has broad training and expertise in intervention research, mixed methods, and in leading a range of federally funded research initiatives. His research goal is to use community-based participatory research (CBPR) to develop and validate school-based aggression and bullying intervention programs and assessment tools for urban minority youth.
Dr. Lerman's research interests include non-infectious uveitis and temporomandibular (TMJ) arthritis. Her studies examine the utility of biologic agents to achieve, and maintain, uveitis control. Up to 80 percent of children with juvenile idiopathic arthritis (JIA) have potentially erosive TMJ arthritis, and she is exploring ways to best identify and monitor this often asymptomatic manifestation of JIA.
Dr. Levine has an active laboratory research program that complements and extends his clinical studies. He has identified the molecular basis of several inherited disorders of mineral metabolism. His research interests extend to the molecular basis for embryological development of the parathyroid glands.
Dr. Levy is the director of Cardiology Research, and also serves as program director of the Cardiology National Heart, Lung, and Blood Institute (NHLBI) Research Training Grant. His research interests are the pathophysiology of biomaterials used in medicine, basic mechanisms and novel therapies for heart valve disease, arterial angioplasty, local drug delivery, and nanomedicine. He also has experience over three decades in medical device development.
Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.
Dr. Lewis is a lead member of the CHOP Zero Suicide Program and a member of the CHOP Youth Suicide Prevention, Intervention and Research Center. He has research and quality improvement interest in the area of youth suicide prevention.
Dr. Li’s methodology research interests include clinical trial design, survival analysis, longitudinal data analysis, and statistical methods for health services research. The current focus of her research is on statistical designs and analyses for early phase cancer clinical trials, such as Bayesian adaptive designs for dose-finding trials and platform trials. Her collaborative research focuses on pediatric oncology, ranging from translational research to clinical trials and epidemiology studies.
Dr. Liao is a pediatric plastic surgeon-scientist and the founding director of the Center for Craniofacial Innovation at Children's Hospital of Philadelphia. His research leverages convergent advances in fetal care, human genetics, and developmental biology to initiate first-in-child trials and treatments.
Dr. Licht is the director of the Wolfson Family Laboratory for Clinical and Biomedical Optics. His research focuses on the development and use of novel noninvasive optical devices to probe cerebrovascular hemodynamics and physiology in vivo. These devices are used in clinical and preclinical studies to discover the timing and causes of brain injury during care.
Dr. Lin studies RNA modifications (a.k.a "epitranscriptomics") in human diseases, including cancer. She develops and applies high-throughput sequencing strategies and transcriptome engineering technologies to study the regulation and function of RNA modifications, including A-to-I RNA editing and m6A RNA methylation.
Dr. Lindell’s research program is centered on the biology of critical illness in children with immune dysfunction. His current translational research is focused on pediatric septic shock and the development of multiple organ dysfunction syndrome (MODS) in critically-ill children.
Dr. Lisanti's research focuses on understanding the influence of individualized family-centered developmental care (IFDC) on infants with congenital heart disease and their families. She is investigating the biobehavioral mechanisms that influence parent stress and mental health symptoms, with the ultimate goal of discovering biological and psychosocial links between parent mental health and child developmental outcomes.
Bone disorders exact a considerable toll on human health in both children and adults. Dr. Long seeks to understand the fundamental mechanisms underlying both normal skeletal development and the pathophysiology of bone diseases. His current research includes studies of skeletal stem cells and progenitors, metabolic regulation of bone cells, and the integration of bone and whole-body metabolism.
Dr. Loomes' research is focused on clinical and translational studies in pediatric liver disease. She works with National Institutes of Health-funded national consortia to conduct studies investigating the etiology and treatment for rare pediatric liver diseases including biliary atresia, Alagille syndrome, and others. Dr. Loomes also collaborates with other investigators at Children’s Hospital of Philadelphia to investigate genetic causes of pediatric liver disease.
Dr. Lorch's research involves understanding the root causes for variations in health outcomes and healthcare utilization experienced by high-risk children, particularly those born prematurely. He is particularly interested in the role of local and state policies on the observed variation in outcomes of premature infants, such as the impact of certificate of need programs on such outcomes.
Dr. Lowenthal's work is focused on addressing health priorities for children in resource-limited settings. In addition to research projects she serves as research director for the Children's Hospital of Philadelphia Global Health Center, supporting junior researchers (and senior researchers newly working in international settings) to develop projects addressing other health priorities for children in resource-limited settings.
Dr. Luberti leads DBHi's informatics education program as medical director, where he helped develop a robust array of seminar and educational series, curriculum-focused informatics initiatives, and collaborations with informatics programs throughout the Philadelphia area and beyond.
Dr. Luo’s clinical research involves employing a variety of techniques to evaluate genetic and genomic alterations for integrated diagnosis of both constitutional disorders and cancer, and to understand the mechanisms of genomic changes.